Zentalis Pharmaceuticals Presents Updated Clinical Data at Society of Gynecologic Oncology

 Azenosertib median duration of response (mDOR) updated to 6.3 months in the ongoing DENALI Part 1b clinical trial in patients with platinum-resistant ovarian cancer (PROC) and continues to demonstrate an objective response rate (ORR) of ~35% in response-evaluable patients

On track to initiate Part 2 of the ongoing DENALI clinical trial in 1H 2025, with registration-intent topline data anticipated by year end 2026

Company also presents preclinical combination data of azenosertib with microtubule inhibitor-based antibody drug conjugates (ADCs) demonstrating synergistic antitumor effects

https://www.globenewswire.com/news-release/2025/03/15/3043285/0/en/Zentalis-Pharmaceuticals-Presents-Updated-Clinical-Data-at-the-Society-of-Gynecologic-Oncology-2025-Annual-Meeting-on-Women-s-Cancer.html